BPC-157 for Adductor Strains: Canada Recovery Guide [2026]

BPC-157 is a synthetic peptide derived from human gastric juice proteins that shows remarkable potential for accelerating adductor strain recovery.

Research demonstrates enhanced tissue repair through increased blood vessel formation, improved collagen organization, and faster fibroblast activity at injury sites.

Standard protocols for adductor strains typically involve 0.25 to 0.5 mg daily via subcutaneous injection near the injured groin area for 4 to 8 weeks.

Many users report noticeable pain reduction and improved mobility within the first week, with significant healing improvements continuing throughout the protocol.

When combined with proper rest and rehabilitation, BPC-157 may reduce typical adductor strain recovery times by several weeks compared to conventional treatment alone.

My name is Nathan Brooks and I play recreational hockey here in Hamilton, Ontario. Last February I pulled my groin pretty bad during a game when I tried to make a quick lateral move. The pain was immediate and sharp. My doctor told me it was a Grade 2 adductor strain and that I should expect at least six to eight weeks before getting back on the ice.

A friend who works in sports medicine mentioned BPC-157 to me. After doing my own research, I decided to try it alongside my physio exercises. I started with 0.25 mg injected subcutaneously about two inches from the sore spot each morning.

My Protocol: 0.25 mg BPC-157 daily for six weeks, injected subcutaneously near the inner thigh, approximately two inches from the injury site. I continued my prescribed physiotherapy exercises and avoided hockey for the first three weeks.

By day four, the constant dull ache had dropped significantly. By week two, I could do the adductor stretches my physio gave me without wincing. I returned to skating at week four and played my first game back at week five. My physiotherapist was surprised at how quickly the tenderness had resolved. Six months later, no re-injury and I feel stronger than before. I cannot say for certain what percentage was the peptide versus just healing naturally, but the timeline beat every estimate I was given.

Understanding Adductor Strains

What Is BPC-157?

How BPC-157 Supports Muscle Healing

Scientific Evidence for Soft Tissue Repair

Dosing Protocols for Adductor Injuries

Injection Technique and Administration

Expected Recovery Timeline

Stacking BPC-157 with TB-500

Integrating BPC-157 with Rehabilitation

Safety Profile and Considerations

Quality Sourcing in Canada

Training Modifications During Recovery

Comparing Recovery Approaches

Long-Term Injury Prevention

Frequently Asked Questions

Glossary

References

Understanding Adductor Strains

The adductor muscle group runs along the inner thigh, connecting your pelvis to your femur and knee. These muscles perform a critical function in stabilizing your hips and bringing your leg toward your body’s midline. Athletes who play hockey, soccer, tennis, and basketball are especially prone to adductor injuries because these sports demand rapid acceleration, sudden direction changes, and explosive lateral movements.

When the adductor muscles contract forcefully while already stretched, the muscle fibers can tear. This creates what medical professionals call an adductor strain, though most people simply refer to it as a pulled groin. The severity of these injuries ranges from minor fiber stretching to complete muscle rupture, and healthcare providers classify them using a three-tier grading system.

The adductor longus muscle sustains damage most frequently among the adductor group. This muscle originates at the pubic bone and inserts along the femur, placing it under substantial mechanical stress during athletic movements. Risk factors for adductor strains include previous groin injuries, inadequate warm-up routines, muscle fatigue, reduced flexibility, and strength imbalances between the adductor and abductor muscle groups.

Traditional treatment for adductor strains follows the RICE protocol in the acute phase: rest, ice, compression, and elevation. Physical therapy then guides patients through progressive strengthening and stretching exercises. While most adductor strains heal with conservative management, the timeline can frustrate active individuals. This is where regenerative peptides like BPC-157 have captured attention for their potential to accelerate the natural healing process.

What Is BPC-157?

Body Protection Compound-157 is a synthetic peptide consisting of 15 amino acids. Scientists derived its sequence from a protective protein naturally present in human gastric juice. The original compound, called BPC, plays a role in maintaining the integrity of the gastrointestinal lining. Researchers isolated and stabilized a specific segment of this protein, creating BPC-157 for research purposes.

Unlike many compounds used in regenerative medicine, BPC-157 demonstrates remarkable stability. It can withstand the acidic environment of the stomach without breaking down, which explains why oral formulations exist alongside injectable versions. For localized injuries like adductor strains, however, injectable BPC-157 remains the preferred delivery method because it allows for targeted administration near the damaged tissue.

The peptide has generated significant interest in athletic and biohacking communities due to consistent reports of accelerated healing across various injury types. Animal studies have demonstrated positive effects on tendons, ligaments, muscles, bone, and even the nervous system. While human clinical trial data remains limited, anecdotal reports from users align remarkably well with the outcomes observed in animal research.

BPC-157 arrives as a lyophilized powder requiring reconstitution with bacteriostatic water before use. Proper storage and handling are essential for maintaining the peptide’s integrity. Once reconstituted, the solution should be refrigerated and typically remains stable for three to four weeks.

How BPC-157 Supports Muscle Healing

The healing potential of BPC-157 stems from its ability to influence multiple biological pathways involved in tissue repair. Understanding these mechanisms helps explain why the peptide shows such promise for injuries like adductor strains.

Angiogenesis Enhancement

Damaged tissue requires increased blood flow to receive the oxygen and nutrients necessary for repair. BPC-157 promotes the formation of new blood vessels through a process called angiogenesis. The peptide activates the VEGFR2-Akt-eNOS pathway and increases nitric oxide production, both of which stimulate blood vessel growth. This enhanced vascularization delivers more healing resources to the injury site while also improving waste removal from damaged areas.

Fibroblast Activation

Fibroblasts are the cells responsible for producing collagen and other structural proteins that form the foundation of repaired tissue. BPC-157 activates the FAK-paxillin pathway, which increases fibroblast migration to injury sites. Once there, these cells work more efficiently to lay down new collagen fibers. Research shows that BPC-157 not only increases the quantity of collagen production but also improves the organization and cross-linking of collagen fibers, resulting in stronger healed tissue.

Growth Hormone Receptor Upregulation

One of BPC-157’s unique properties is its ability to increase the expression of growth hormone receptors on tendon and muscle fibroblasts. This means that even with normal growth hormone levels, damaged tissue becomes more responsive to growth signals. The practical result is enhanced cellular proliferation and faster tissue regeneration at the injury site.

Anti-Inflammatory Effects

While inflammation serves an important initial role in healing, prolonged inflammation delays recovery and can contribute to chronic pain. BPC-157 modulates inflammatory responses through the erg-1 transcription factor pathway. This helps transition the injury from the inflammatory phase to the proliferative and remodeling phases more efficiently, without the need for NSAIDs that may impair certain aspects of tissue healing.

Systemic Migration to Damage Sites

Research has revealed something interesting about BPC-157: the peptide naturally migrates toward areas of tissue damage regardless of where it is injected. This property distinguishes it from many other therapeutic compounds that require precise local delivery. For adductor strains, this means that even a slightly imprecise injection will still deliver benefits to the injured muscle fibers.

Angiogenesis

VEGFR2-Akt-eNOS

Increased blood vessel formation

Fibroblast Migration

FAK-paxillin

More repair cells at injury site

GH Receptor Upregulation

Direct receptor expression

Enhanced cellular responsiveness

Anti-Inflammatory

erg-1 inhibition

Faster transition through healing phases

Collagen Organization

Cross-linking enhancement

Stronger repaired tissue

Scientific Evidence for Soft Tissue Repair

The scientific literature on BPC-157 contains hundreds of studies, though the vast majority involve animal models rather than human subjects. This evidence gap represents both the compound’s promise and its current limitations. The consistency of positive outcomes across diverse animal studies suggests real therapeutic potential, while the lack of large-scale human trials means optimal protocols remain somewhat empirical.

Muscle Injury Research

Studies on rat models have demonstrated BPC-157’s ability to accelerate muscle healing following various types of damage. In crush injury models, BPC-157-treated animals showed faster restoration of muscle architecture and improved functional recovery compared to controls. The peptide enhanced satellite cell activation, which is essential for muscle fiber regeneration, and reduced the inflammatory infiltration that can impair healing.

Tendon and Ligament Studies

Perhaps the strongest body of evidence supports BPC-157’s effects on tendon healing. Rat studies involving Achilles tendon transection showed that BPC-157 significantly improved both the structural and functional properties of healed tendons. The treated animals demonstrated better collagen fiber alignment, increased tensile strength, and faster return to normal biomechanical function. Similar results have been observed in studies involving the MCL and other connective tissues.

One particularly relevant finding for adductor injuries: BPC-157 appears effective whether administered locally near the injury or systemically. The peptide’s natural migration toward damaged tissue means that subcutaneous injection in the general area of an adductor strain delivers therapeutic concentrations to the injured fibers.

Comparative Effectiveness

While direct comparison studies are limited, BPC-157 has shown favorable results when evaluated against other regenerative approaches. The peptide’s effects complement rather than compete with platelet-rich plasma (PRP) therapy, and some practitioners now use them in combination. Unlike corticosteroid injections, BPC-157 does not appear to weaken tendon tissue or cause the long-term structural changes associated with repeated steroid use.

Human Evidence

A Phase I clinical trial was initiated in 2015 with 42 healthy volunteers to assess BPC-157 safety in humans. While the trial was marked as “completed,” results were never published, and the manuscript submission was cancelled in 2016. This represents a significant gap in the evidence base. Current human evidence relies primarily on anecdotal reports from athletes, bodybuilders, and biohacking communities.

These reports, while not scientifically rigorous, are numerous and consistent. Users commonly describe noticeable pain reduction within the first week of administration, improved mobility within two weeks, and accelerated return to full activity compared to previous injuries treated conventionally. Re-injury rates among those who complete full protocols appear lower than historical averages, though this has not been formally studied.

Dosing Protocols for Adductor Injuries

Dosing recommendations for BPC-157 derive from extrapolation of animal study data and accumulated user experience. The therapeutic window appears quite wide, with most users experiencing benefits without significant side effects across a range of doses.

Standard Dosing Range

Most protocols for musculoskeletal injuries fall within 0.25 to 0.5 mg per day. This range translates to approximately 1.6 to 4.0 micrograms per kilogram of body weight when scaled from effective animal doses. For a person weighing 175 lb (approximately 80 kg), this means daily doses between 250 and 500 micrograms, typically expressed as 0.25 to 0.5 mg.

Conservative vs. Aggressive Approaches

Beginners should start with 0.2 to 0.25 mg daily to assess individual response and tolerance. More aggressive protocols for severe acute injuries may use 0.75 to 1.0 mg daily for the first three to five days before tapering to the standard range. These higher initial doses aim to provide maximum support during the critical early healing window.

Split Dosing Considerations

Because BPC-157 has a relatively short half-life of approximately four to six hours, split dosing maintains more consistent tissue levels throughout the day. For moderate to severe adductor strains, dividing the daily dose into two administrations separated by 12 hours may provide enhanced benefits. A typical split protocol would involve 0.25 mg in the morning and 0.25 mg in the evening.

Cycling and Duration

Standard protocols recommend running BPC-157 for 4 to 8 weeks depending on injury severity, followed by a 2 to 4 week break. This cycling approach reflects conservative practice rather than established tolerance development. BPC-157 does not suppress natural hormone production, require post-cycle therapy, or demonstrate rebound effects, but periodic breaks allow the body to consolidate healing and reduce theoretical receptor desensitization risks.

For chronic or recurring adductor issues, some users implement maintenance protocols of 0.25 mg daily for 4 to 6 weeks every three to four months. This preventive approach aims to support tissue integrity during high-volume training periods.

Injection Technique and Administration

Proper administration technique maximizes therapeutic benefit while minimizing complications. Injectable BPC-157 uses subcutaneous delivery, which is straightforward to learn but requires attention to detail.

Reconstitution Process

BPC-157 arrives as a freeze-dried powder that must be mixed with bacteriostatic water before use. The water contains 0.9% benzyl alcohol as an antimicrobial preservative, extending the solution’s usable life.

Concentration Calculations

A common reconstitution uses 2 mL of bacteriostatic water with a 5 mg vial, creating a concentration of 2.5 mg per mL. With this concentration, 0.1 mL (10 units on an insulin syringe) delivers 0.25 mg of BPC-157. A 10 mg vial reconstituted with 2 mL yields 5 mg per mL, where 0.1 mL equals 0.5 mg.

Injection Site Selection for Adductor Injuries

For adductor strains, inject subcutaneously approximately 1 to 2 inches from the point of maximum tenderness. Avoid injecting directly into damaged tissue, as this can cause additional discomfort and may not improve results. The peptide will migrate to the injury site from nearby subcutaneous tissue.

Pinch a fold of skin on the inner thigh, insert a 29 to 31 gauge insulin needle at a 45-degree angle, and inject slowly over 5 to 10 seconds. Rotate injection sites slightly each day to prevent tissue irritation. Some users prefer alternating between the injured area and an abdominal site to reduce local tissue stress while maintaining systemic levels.

Storage Requirements

Store unreconstituted BPC-157 in a cool, dry place away from light. Some sources recommend refrigeration even before reconstitution for extended shelf life. Once mixed with bacteriostatic water, always store the solution refrigerated at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). Never freeze reconstituted peptide, as ice crystal formation destroys the molecular structure. Properly stored reconstituted BPC-157 typically remains stable for three to four weeks.

Expected Recovery Timeline

Individual responses to BPC-157 vary, but users report remarkably consistent patterns when treating adductor strains. The timeline below synthesizes common experiences, though your results may differ based on injury severity, overall health, and adherence to complementary rehabilitation.

Setting Realistic Expectations

BPC-157 accelerates natural healing but does not produce miracles. A severe Grade 3 tear will not heal in two weeks regardless of intervention. The peptide appears to compress recovery timelines by 20 to 40 percent based on user reports, meaning a strain that would normally take six weeks might resolve in four to five weeks with BPC-157 support.

Chronic injuries with established dysfunction respond less dramatically than acute injuries. If you have been dealing with groin pain for months or years, expect more modest improvements and longer protocol durations. BPC-157 may improve chronic conditions to 70 to 90 percent of baseline rather than complete resolution.

Stacking BPC-157 with TB-500

The combination of BPC-157 and TB-500 (Thymosin Beta-4) has earned the nickname “Wolverine Stack” within the peptide community for its reportedly enhanced healing effects. These two peptides work through complementary mechanisms, and users consistently report better outcomes with the combination than with either compound alone.

Why the Combination Works

TB-500 excels at systemic regeneration, muscle healing, and reducing inflammation throughout the body. Its low molecular weight allows distribution through the bloodstream to multiple injury sites simultaneously. BPC-157, by contrast, concentrates effects at the injection site while providing additional systemic benefits. The peptides activate different cellular pathways that converge on common healing outcomes.

At the molecular level, BPC-157 increases actin gene expression while TB-500 sequesters and organizes actin for cell movement. BPC-157 upregulates growth hormone receptors on fibroblasts while TB-500 utilizes those receptors for enhanced repair. Both promote angiogenesis but through different signaling pathways. This mechanistic synergy explains why combined use produces results estimated at 30 to 60 percent better than either peptide individually.

Administration Differences

TB-500 can be injected anywhere subcutaneously because it distributes systemically regardless of injection location. Many users inject TB-500 in abdominal fat for convenience. BPC-157, however, benefits from injection near the injury site to maximize local concentration. Administering TB-500 and BPC-157 at different sites during the same session is common practice.

When to Consider the Stack

The combination is particularly valuable for moderate to severe adductor strains, recurring groin injuries, athletes needing rapid return to competition, and situations involving multiple injury sites. For mild Grade 1 strains in recreational athletes, BPC-157 alone often suffices and represents a more cost-effective option.

Integrating BPC-157 with Rehabilitation

BPC-157 enhances healing but does not replace proper rehabilitation. The peptide works best as part of a comprehensive recovery approach that includes appropriate rest, progressive exercise, and professional guidance when needed.

The Mistake of Training Through Pain

One of the most common errors users make is assuming that BPC-157 allows them to bypass necessary rest. The peptide accelerates healing but cannot override continued tissue damage from premature activity. Athletes who return to full training immediately after starting BPC-157 often fail to see expected benefits because they keep re-traumatizing the healing tissue.

Progressive Loading Principles

Follow your physiotherapist’s guidance on when to progress through rehabilitation stages. Generally, the early phase focuses on pain-free range of motion and gentle stretching. As tolerance improves, isometric strengthening begins, followed by dynamic exercises with progressive resistance. Sport-specific movements come last, only after strength and flexibility have been adequately restored.

BPC-157 may allow faster progression through these stages, but each stage should still be completed. The peptide supports tissue repair at the cellular level while rehabilitation ensures proper neuromuscular function and movement patterns.

Complementary Strategies

Several approaches enhance BPC-157’s effects when recovering from an adductor strain:

When to Seek Professional Help

Consult a sports medicine physician or physiotherapist if pain persists beyond expected timelines, if you experience any unusual symptoms during BPC-157 use, or if you are uncertain about injury severity. Professional imaging such as MRI or ultrasound can clarify the extent of tissue damage and guide appropriate treatment intensity.

Safety Profile and Considerations

BPC-157 demonstrates a favorable safety profile in both animal research and accumulated user experience. No significant adverse events have been documented in animal studies even at doses far exceeding typical human protocols. However, the lack of long-term human clinical data means some uncertainty remains.

Reported Side Effects

Most users report minimal to no side effects when using BPC-157 at standard doses. When side effects do occur, they tend to be mild and transient:

Theoretical Concerns

Because BPC-157 promotes angiogenesis and cell proliferation, questions have been raised about its use in individuals with active cancer or high cancer risk. While no evidence connects BPC-157 to cancer development or progression, those with active malignancies or concerning family histories should discuss any peptide use with their oncologist.

Contraindications and Precautions

BPC-157 is not recommended during pregnancy or breastfeeding due to lack of safety data in these populations. Individuals on blood thinners should exercise caution given BPC-157’s effects on vascular tissue. Those with autoimmune conditions should monitor for any changes in symptoms, as immune modulation effects are not fully characterized.

Quality-Related Safety

The most significant safety variable is product quality. Contaminated or degraded peptides pose risks that properly manufactured BPC-157 does not. Studies have found that 12 to 58 percent of ergogenic supplements contain contaminants, 30 percent have incorrect amino acid sequences, and 65 percent exceed safe endotoxin thresholds. Sourcing from reputable suppliers with third-party testing documentation is essential for safety.

Quality Sourcing in Canada

Canadians face unique considerations when obtaining research peptides like BPC-157. The compound is not approved by Health Canada for medical use and cannot be legally prescribed by physicians. It exists in a regulatory gray area as a research chemical, available for purchase for research purposes.

Verification Standards

When evaluating any peptide supplier, prioritize those who provide Certificates of Analysis (COA) from independent third-party laboratories. Look for documentation showing purity levels of 98% or higher, with 99%+ being preferable. The COA should include the batch number matching your product and testing by a recognized analytical laboratory.

Red Flags to Avoid

Be wary of suppliers offering prices significantly below market norms, as quality peptide synthesis is not inexpensive. Absence of COA documentation, unclear information about peptide sequence or synthesis methods, and lack of established reputation all suggest potential quality issues. Generic packaging without proper labeling and customer service that cannot answer basic questions about their products are additional warning signs.

Canadian Supplier Considerations

Domestic Canadian suppliers offer advantages including faster shipping, no customs concerns, and easier communication. Red Fox Peptides provides research-grade BPC-157 with documented purity testing, domestic shipping across Canada, and customer support familiar with Canadian research community needs. Pricing in Canadian dollars eliminates currency conversion uncertainty.

Storage After Purchase

Once you receive BPC-157, proper storage preserves potency. Unreconstituted powder should be kept in a cool, dark place and can be refrigerated for extended shelf life. After reconstitution, always refrigerate and use within three to four weeks. Protect from light, heat, and contamination to maintain full effectiveness throughout your protocol.

Training Modifications During Recovery

Successfully recovering from an adductor strain requires more than just peptide support. How you modify your training during the healing period significantly impacts both the speed and quality of your recovery. Many athletes make the mistake of either complete inactivity or premature return to normal training, both of which can compromise outcomes.

The Active Recovery Approach

Complete rest is necessary during the acute phase immediately following injury, typically the first 48 to 72 hours. Beyond this window, however, appropriate movement promotes healing by increasing blood flow, preventing muscle atrophy, and maintaining neuromuscular connections. The key lies in selecting activities that load the healing tissue progressively without exceeding its current tolerance.

Low-impact cardiovascular exercise can typically resume within the first week for most Grade 1 and 2 strains. Pool exercises are particularly valuable because water provides resistance while supporting body weight. Swimming using primarily the arms, water walking, and gentle aquatic exercises allow cardiovascular maintenance without stressing the adductors.

Upper Body Training Considerations

Most upper body exercises can continue throughout adductor recovery with appropriate modifications. Seated exercises eliminate lower body involvement entirely. Movements like chest press, shoulder press, rows, and arm exercises performed from a bench or chair keep you training without loading the groin area.

Standing upper body exercises require more caution. Any exercise requiring hip stability may inadvertently engage the adductors. Wide stances, lateral movements, and exercises involving rotation through the hips should be avoided until the later stages of recovery. When in doubt, sit down.

Lower Body Training Progression

The return to lower body training follows a careful progression that respects tissue healing timelines. This progression should be guided by pain levels rather than arbitrary time periods, as individual healing rates vary considerably.

Exercises to Avoid During Recovery

Certain exercises place excessive stress on the adductors and should be eliminated until full healing is achieved. Wide-stance squats and deadlifts require significant adductor engagement for hip stability. Sumo deadlifts are particularly problematic due to the extreme hip abduction position. Lunges, especially lateral lunges, create both stretching and loading forces on the inner thigh.

Explosive movements like box jumps, sprint starts, and plyometrics demand rapid adductor activation and should be among the last activities to return. Sports-specific cutting, pivoting, and lateral shuffle movements also require full tissue recovery before resumption.

Sport-Specific Return Protocols

Different sports demand different recovery considerations. Hockey players face particular challenges because skating requires significant adductor work for both propulsion and stability. A gradual return might begin with easy skating, progress to harder pushes, then add stops and starts, and finally incorporate game-speed situations.

Soccer players should progress from jogging to running to sprinting before adding ball work. Kicking drills begin with short passes and gradually increase power. Cutting and pivoting movements come last, often requiring three to four weeks of progressive exposure before match readiness.

Tennis players can typically rally from baseline before serving power returns. The service motion and wide lateral movement to retrieve shots are the final elements to restore. Many players find they can return to recreational play before competitive singles matches.

Comparing Recovery Approaches

Athletes and active individuals have several options for supporting adductor strain recovery. Understanding how BPC-157 compares to other approaches helps inform treatment decisions. Each approach has distinct advantages, limitations, and cost considerations.

Conventional Treatment Alone

Standard medical care for adductor strains involves RICE protocol during the acute phase followed by progressive physical therapy. This approach carries no additional costs beyond potential physiotherapy sessions and is supported by extensive clinical evidence. Recovery timelines are well-established, with most Grade 1 strains resolving in two to three weeks and Grade 2 strains requiring three to six weeks.

The limitation of conventional treatment alone is that it relies entirely on the body’s natural healing rate without augmentation. For athletes facing competition deadlines or active individuals whose livelihoods depend on physical function, this timeline may be problematic.

Platelet-Rich Plasma (PRP) Therapy

PRP injections concentrate growth factors from your own blood and deliver them to the injury site. The treatment has substantial clinical trial support for various musculoskeletal conditions. Healthcare professionals administer PRP in clinical settings, providing direct medical oversight.

PRP costs range from $285 to $500+ per injection in Canada, with some injuries requiring multiple sessions. The treatment involves blood draw, centrifugation, and injection, typically taking 30 to 60 minutes in a medical facility. Results vary based on preparation technique and delivery method.

Approximate Cost

$0-200

$285-1000+

$80-200

Clinical Evidence

Extensive

Substantial

Animal studies

Medical Supervision

Optional PT

Required

Self-administered

Treatment Duration

Ongoing

1-3 sessions

4-8 weeks

User Reports

Predictable

Variable

Positive

BPC-157 as Augmentation

BPC-157 offers several practical advantages for self-directed recovery support. The cost is modest compared to clinical interventions, and administration does not require medical appointments. Users report consistently positive experiences with few side effects.

The primary limitation remains the lack of published human clinical trials. While animal research is extensive and promising, translation to human outcomes relies on anecdotal evidence. For those comfortable with this evidence gap, BPC-157 provides an accessible option for recovery enhancement.

Combination Approaches

These approaches are not mutually exclusive. Some athletes use BPC-157 alongside physical therapy to accelerate their rehabilitation timeline. Others combine PRP injection for immediate growth factor delivery with BPC-157 for sustained healing support over the following weeks.

When combining approaches, timing considerations apply. PRP is typically administered once or twice during recovery. BPC-157 protocols run continuously for four to eight weeks. The two can be used concurrently, with some practitioners recommending BPC-157 both before and after PRP treatment to optimize the tissue environment for growth factor activity.

Long-Term Injury Prevention

Recovering from an adductor strain provides an opportunity to address the factors that contributed to injury in the first place. Without correcting these underlying issues, re-injury risk remains elevated even after complete healing. Research shows that previous adductor strain is the strongest predictor of future adductor strain.

Addressing Strength Imbalances

Weakness in the adductor muscles relative to the abductors and hip flexors creates mechanical vulnerability. Targeted strengthening should become part of your regular training once acute recovery is complete. Copenhagen adductor exercises have strong research support for both rehabilitation and prevention.

The standard Copenhagen exercise has you side-lying with your top leg supported on a bench while you raise and lower your body using adductor strength. This exercise can be progressed from short lever positions to full-length positions and eventually to dynamic variations. Three sets of eight to twelve repetitions, two to three times per week, significantly reduces adductor injury risk.

Flexibility and Mobility Work

Limited hip flexibility increases adductor strain risk by forcing the muscles to work through inadequate range of motion. Regular hip mobility work should address both adductor flexibility and overall hip joint movement. Dynamic stretching before activity and static stretching after activity provides a balanced approach.

The adductor rock-back stretch is particularly effective for maintaining inner thigh flexibility. From a quadruped position with one leg extended to the side, rock your hips back toward your heels while keeping the extended leg straight. Hold for 30 seconds and repeat two to three times per side.

Warm-Up Protocols

Inadequate warm-up is a consistent factor in adductor injuries. Cold muscles are less elastic and more prone to strain under sudden load. An effective warm-up for adductor protection should include general cardiovascular activity, dynamic hip mobility drills, and sport-specific movement patterns at gradually increasing intensity.

A complete warm-up takes fifteen to twenty minutes and should raise core temperature enough to produce light sweating. Rushing this process to save time is a false economy when weighed against potential injury downtime.

Load Management

Sudden increases in training volume or intensity are a common trigger for soft tissue injuries. The adductors can tolerate high loads when properly conditioned but fail when exposed to demands beyond their current capacity. Progressive overload principles apply to injury prevention just as they do to performance improvement.

When returning from injury or after a layoff period, increase training loads by no more than ten percent per week. Allow adequate recovery between high-intensity sessions. Listen to warning signs like unusual tightness or soreness in the groin area and reduce load when these appear.

Preventive Peptide Protocols

Some athletes use BPC-157 preventively during periods of high training stress. A typical preventive protocol involves 0.25 mg daily for four to six weeks during preseason training or when significantly increasing training volume. The rationale is that BPC-157’s tissue-protective effects may help the adductors adapt to increased demands without breaking down.

While not rigorously studied, this approach has theoretical merit given BPC-157’s effects on collagen quality and tissue resilience. Athletes who have experienced previous adductor injuries may find preventive protocols particularly valuable for maintaining their investment in full recovery.

Frequently Asked Questions

Glossary

References

↑ Menu